Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne (NASDAQ: TECH) has announced two significant shareholder returns initiatives. The company declared a quarterly dividend of $0.08 per share, payable on May 30, 2025, to shareholders of record as of May 19, 2025. Additionally, the Board approved a new $500 million share repurchase program effective May 8, 2025, replacing the previous program.

The timing and volume of share repurchases will be determined by various factors including share price, market conditions, and regulatory requirements. Bio-Techne, a global life sciences company providing research and clinical diagnostic tools, reported $1.2 billion in net sales for fiscal 2024 and employs approximately 3,100 people worldwide.

Bio-Techne (NASDAQ: TECH) reported its Q3 FY2025 financial results with organic revenue growth of 6% to $316.2 million. The company's GAAP EPS decreased to $0.14 from $0.31 year-over-year, while adjusted EPS improved to $0.56 from $0.48. The Protein Sciences segment showed strong performance with 7% organic growth to $227.7 million, driven by improved pharma end market conditions. The Diagnostics and Spatial Biology segment grew 2% to $89.2 million. The company achieved an adjusted operating margin of 34.9%, up from 33.0% in the prior year, benefiting from profitability initiatives and volume leverage. However, GAAP operating margin declined to 12.2% from 22.1%, impacted by a non-recurring arbitration award.

ScaleReady has awarded a $300,000 G-Rex® Grant to A2 Biotherapeutics to support process development and evaluation of G-Rex for manufacturing cell therapies. The grant enables A2 to explore the G-CART process, a standardized workflow for CAR-T drug product manufacturing, developed by Cell Ready.

A2 will evaluate this platform for their proprietary Tmod™ platform, a dual-signal integrator system for cancer cell therapy targeting various solid tumor indications including colorectal, lung, pancreatic, and ovarian cancers. The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, has been extended with millions in additional funding.

ScaleReady has awarded a $200,000 G-Rex® Grant to March Biosciences to advance the manufacturing of MB-105, a novel CAR-T cell therapy. The therapy targets CD5 for patients with T-cell lymphomas and received FDA orphan drug designation in January 2025.

MB-105 is being developed for multiple CD5-positive blood cancers, including T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma. The therapy's proprietary design allows it to target malignant cells while preserving normal T-cell function.

The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, provides up to $300,000 per recipient. Grant recipients gain access to ScaleReady's consortium of partners, offering expertise in:

• cGMP manufacturing
• Quality and regulatory affairs
• CGT business operations

The program has been extended with millions in additional funding to continue supporting cell and gene therapy development.

Bio-Techne (NASDAQ: TECH) has announced an Early Access Program for a new spatial protein proximity detection assay, built on RNAscope™ technology. The next-generation assay enables high-resolution visualization of protein interactions within intact tissues, providing functional insights into disease processes.

The technology addresses limitations of conventional methods by offering clear visual signals at subcellular resolution, compatible with the RNAscope™ Multiomic LS workflow on BOND RX. This advancement is particularly valuable for research in immune checkpoint dynamics, bispecific antibodies, and synaptic junction protein interactions.

The Early Access Program will be available to select institutions and researchers, with proof-of-concept data and case studies to be presented at the 2025 American Association for Cancer Research (AACR) annual meeting.

Bio-Techne (NASDAQ: TECH) has announced its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting from April 25-30 in Chicago. The company will showcase its oncology research portfolio at two booths:

At booth #3049, Bio-Techne will display its comprehensive portfolio including proteins, antibodies, cell culture reagents, and spatial multiomic solutions. Advanced Cell Diagnostics (ACD) will feature its RNAscope™ spatial portfolio and host an evening reception on April 27th.

At booth #3249, Lunaphore will present its spatial biology solutions, including a new fully-automated, same-section multiomics application for fixed-frozen tissue. The company will host a dinner reception on April 28th to showcase its HORIZON™ image analysis software.

The company will also present multiple scientific posters covering topics such as protein quantitation, biomarker evaluation, and spatial multiomics analysis in cancer research.

OmniAb (NASDAQ: OABI) has announced two strategic appointments to its Board of Directors: Philip J. Gotwals, Ph.D., and Steve Crouse, while Director Sarah Boyce steps down after nearly six years of service. These changes increase the board size to seven members.

Dr. Gotwals brings 30 years of biopharmaceutical experience, notably as Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research, where his team executed over 50 major strategic transactions. He will serve on the Human Capital Management & Compensation Committee and Science & Technology Committee.

Steve Crouse, currently Senior Vice President and General Manager of Bio-Techne's Analytical Solutions Division, contributes over 20 years of life sciences expertise. He will serve on the Audit Committee and Science & Technology Committee.

Bio-Techne (NASDAQ: TECH) has announced its upcoming third quarter fiscal 2025 financial results conference call and webcast, scheduled for Wednesday, May 7, 2025, at 8:00 a.m. CDT. Investors can access the live discussion through phone dial-in (1-877-407-9208 for domestic, 1-201-493-6784 for international callers) using Conference ID 13753150 or via webcast on the company's investor relations website.

For those unable to attend the live call, a recorded rebroadcast will be available from 11:00 a.m. CDT on May 7 until 11:00 p.m. CDT on June 7, 2025, accessible by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).

Bio-Techne (NASDAQ: TECH) has expanded its partnership with Leica Biosystems to enhance spatial multiomics research capabilities. The collaboration focuses on automating Bio-Techne's new RNAscope™ Multiomic LS Assay on Leica's BOND RX research staining instrument.

The assay enables simultaneous detection of up to six RNA and/or protein biomarkers on a single slide while preserving sample integrity. Additionally, they introduced a protease-free workflow for RNAscope™ 2.5 single-plex assays. The RNAscope™ technology has been widely adopted globally, contributing to over 12,000 peer-reviewed publications.

This expansion builds upon their partnership established in 2015, focusing on automated in-situ hybridization workflows for spatial biology research.